TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26984105

Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HV), six sets/exercise, 70% of one maximal repetition, three times a week for 16 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (LV), three sets/exercise, 70% of one maximal repetition, three times a week for 16 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CT, no exercise)
Number of subjects: 32
Study: 26362793

Group type: EXPERIMENTAL
Intervention: TCM acupuncture
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 34
Study: 22463885

Group type: COMPARATOR
Intervention: Transjugular intrahepatic portasystemic shunt (TIPS)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Small-diameter prosthetic H-graft portacaval shunt (HGPCS)
Number of subjects: 132
Study: 20506371

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 18336547

Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium longum strains (2C and 46)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Commercial control (Bifidobacterium lactis Bb-12)
Number of subjects: 55
Study: 16116971

Group type: EXPERIMENTAL
Intervention: CPA + metformin (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CPA (n = 25)
Number of subjects: 50
Study: 14503550

Group type: EXPERIMENTAL
Intervention: New therapeutic approaches targeting epithelial cells, myofibroblasts, and chronic inflammation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy of corticosteroids and cytotoxic medications
Number of subjects: 0
Study: 10678454

Group type: EXPERIMENTAL
Intervention: Listening for spectral shifts in ambient sound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated listener motion
Number of subjects: 0
Study: 8672151

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (chemotherapy and radiotherapy followed by surgery)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 113
Study: 1925820

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nifedipine and Captopril)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nifedipine (10 mg) and Captopril (25 mg)
Number of subjects: 20
Study: 6388722

Group type: EXPERIMENTAL
Intervention: BICAP bipolar electrocoagulation treatment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Stigmata of recent hemorrhage
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 129
Study: 30952032

Group type: EXPERIMENTAL
Intervention: CHORDATA® method (body suspension and pendulum exercises)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 29804953

Group type: EXPERIMENTAL
Intervention: 5-strand hamstring autograft technique
Number of subjects: 64

Group type: COMPARATOR
Intervention: Quadrupled semitendinosus-gracilis autograft
Number of subjects: 64
Study: 26871851

Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase for 7 days, followed by maintenance therapy of pancreatic kallikrein for 6 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 25144133

Group type: EXPERIMENTAL
Intervention: 6 mg·kg of caffeine (CAF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 22331946

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP) 80 mg/m² for 12 weeks followed by FEC (fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²) every 3 weeks for four cycles
Number of subjects: 601

Group type: COMPARATOR
Intervention: Docetaxel (XT) 75 mg/m² on day 1 and capecitabine (1,500 mg/m² on days 1 through 14) every 3 weeks for four cycles followed by FEC for four cycles
Number of subjects: 601

Group type: COMPARATOR
Intervention: Docetaxel (XT)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP)
Number of subjects: 601
Study: 20644207

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride and Placebo
Number of subjects: 101
Study: 17959981

Group type: EXPERIMENTAL
Intervention: Oral pregabalin 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17321219

Group type: EXPERIMENTAL
Intervention: Randomized Play-the-Winner (RPW) treatment allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 14722890

Group type: EXPERIMENTAL
Intervention: Aerosol administration of Edmonston-Zagreb measles vaccine (10^3.6 pfu/dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous administration of Edmonston-Zagreb measles vaccine (10^4.27 pfu/dose)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aerosol administration of Edmonston-Zagreb measles vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Subcutaneous administration of Edmonston-Zagreb measles vaccine
Number of subjects: 100
Study: 11288792

Group type: EXPERIMENTAL
Intervention: EMD + AB (Enamel Matrix Proteins + Antibiotics)
Number of subjects: 34

Group type: COMPARATOR
Intervention: EMD (Enamel Matrix Proteins)
Number of subjects: 34
Study: 9709314

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of clinical indicators of c-spine injury
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of alteration in consciousness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of evidence of intoxication
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of complaint of neck pain
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of cervical tenderness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of neurologic deficit or complaint
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paramedic assessment of distracting injury
Number of subjects: 20
Study: 8422488

Group type: EXPERIMENTAL
Intervention: Blood conservation techniques including withdrawal of blood before surgery, intraoperative blood salvage with Solcotrans, and profound hemodilution
Number of subjects: 28

Group type: COMPARATOR
Intervention: Profound hemodilution only during cardiopulmonary bypass (CPB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Blood conservation techniques
Number of subjects: 28
Study: 3521856

Group type: EXPERIMENTAL
Intervention: Desoximetasone gel 0.05%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Fluocinonide gel 0.05%
Number of subjects: 125
Study: 31189129

Group type: EXPERIMENTAL
Intervention: Procollagen type 1 N-terminal propeptide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic peptide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sclerostin
Number of subjects: 15
Study: 28241237

Group type: EXPERIMENTAL
Intervention: Testosterone gel (dose adjusted to maintain normal testosterone levels for young men)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 788

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 788
Study: 25853877

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/d for the first 5 days followed by 5 g/d for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (same amount as creatine for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no supplementation or exercise)
Number of subjects: 60
Study: 24043457

Group type: EXPERIMENTAL
Intervention: Transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel
Number of subjects: 30
Study: 21823917

Group type: EXPERIMENTAL
Intervention: computer-delivered brief intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: assessment-only conditions
Number of subjects: 50
Study: 19059933

Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir (0.5 mg/kg) every 2 weeks for a total of six doses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-cidofovir treatment (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-dose cidofovir
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acute rejection prior to PVAN diagnosis
Number of subjects: 14
Study: 17076315

Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roth's ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acid etching (control)
Number of subjects: 0
Study: 15353407

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 12
Study: 11250100

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In vitro erythrocyte partitioning of nitrendipine
Number of subjects: 40
Study: 9612115

Group type: EXPERIMENTAL
Intervention: EGb 761 (3 times 1 film-coated tablet daily for 24 weeks)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (3 times 1 film-coated tablet daily for 24 weeks)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 7734800

Group type: EXPERIMENTAL
Intervention: PTHF1 (100% whey hydrolysate)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PTHF2 (78% whey and 22% casein hydrolysed)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PTHF3 (78/22 enriched with histidine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard preterm formula (whey/casein: 60/40)
Number of subjects: 19
Study: 2734718

Group type: EXPERIMENTAL
Intervention: Theophylline (Planphylline) 10 mg/kg/day in two doses at 8.30 a.m. and 8.30 p.m.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31077596

Group type: EXPERIMENTAL
Intervention: Cat-PAD (peptide immunotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28049069

Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral training delivered in a group
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral training delivered via the internet
Number of subjects: 251

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 251
Study: 24885307

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) - SMR protocol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) - UA protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 30
Study: 23218193

Group type: EXPERIMENTAL
Intervention: Statin therapy (≥ 28 cDDDs)
Number of subjects: 171885

Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs 28 to 90)
Number of subjects: 171885

Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs 91 to 365)
Number of subjects: 171885

Group type: EXPERIMENTAL
Intervention: Statin therapy (cDDDs > 365)
Number of subjects: 171885

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 171885
Study: 21502887

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 15
Study: 19333948

Group type: EXPERIMENTAL
Intervention: 10 microg/kg/day recombinant human relaxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 microg/kg/day recombinant human relaxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxin therapy (both doses)
Number of subjects: 0
Study: 16906265

Group type: EXPERIMENTAL
Intervention: Greater-than-5% weight reduction
Number of subjects: 47
Study: 15521115

Group type: EXPERIMENTAL
Intervention: Communication-trained doctors with access to a computer-based information tool on FMS (IG I)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Standard doctors with access to the information tool on FMS (IG II)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard doctors with no additional information (Control Group - CG)
Number of subjects: 133
Study: 11320044

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (12.5 mg/kg, every six hours for 14 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo solution (normal saline)
Number of subjects: 56
Study: 9015657

Group type: EXPERIMENTAL
Intervention: 4-day head-down bed rest (HDBR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 4-day confinement (C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HUT and LBNP after HDBR and confinement
Number of subjects: 8
Study: 8258511

Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with suspected glaucoma
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with glaucoma
Number of subjects: 70
Study: 2959308

Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betahistine (H1-receptor agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Impromidine (H2-receptor agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral terfenadine 120 mg (pretreatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral cimetidine 400 mg (pretreatment)
Number of subjects: 12
Study: 30040760

Group type: EXPERIMENTAL
Intervention: Virtual reality robot‐assisted gait training (VRGT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auditory stimulation robot‐assisted gait training (ARGT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (general physical therapy)
Number of subjects: 40
Study: 28199892

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Brief therapy (BT)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Prognostic index (PI)
Number of subjects: 622
Study: 26625516

Group type: EXPERIMENTAL
Intervention: Fixed combination of Lisinopril and Amlodipine
Number of subjects: 30
Study: 22608892

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 22092784

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 16
Study: 18417083

Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: No Radiation Therapy (RT) after Breast-Conserving Surgery (BCS)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Geographic Region (West vs. Midwest)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Surgeon Specialty (Surgical Oncologists vs. General Surgeons)
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Factors influencing RT use
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Patient Age, Geographic Region, Surgeon Specialty
Number of subjects: 1222
Study: 16601648

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48
Study: 14765000

Group type: EXPERIMENTAL
Intervention: Lower whole brain volume (WBV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lower Hachinski score
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cortical stroke evidence at baseline
Number of subjects: 30

Group type: COMPARATOR
Intervention: No clinical variables
Number of subjects: 30
Study: 12212127

Group type: EXPERIMENTAL
Intervention: Inhalation of 20 ppm nitric oxide (NO) during the early phase of reperfusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no nitric oxide inhalation)
Number of subjects: 20
Study: 9116275

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy (5 to 10 mg/kg/d) after 32P treatment
Number of subjects: 461

Group type: COMPARATOR
Intervention: 32P treatment alone
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) maintenance therapy in severe cases with rapid recurrence
Number of subjects: 461
Study: 7960627

Group type: EXPERIMENTAL
Intervention: Volumetric acquisitions with intravenous gadolinium
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Two-dimensional interleaved gradient-recalled-echo pulse sequences with intravenous gadolinium
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Phased-array coils
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional time-of-flight techniques
Number of subjects: 14
Study: 2884811

Group type: EXPERIMENTAL
Intervention: Dixyrazine (50 mg/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 31715274

Group type: EXPERIMENTAL
Intervention: Rapid responders (≥80% decrease in level of AST after 8 weeks of treatment with predniso(lo)ne)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Rapid responders
Number of subjects: 740

Group type: COMPARATOR
Intervention: Non-rapid responders
Number of subjects: 740
Study: 30601172

Group type: EXPERIMENTAL
Intervention: 110 μm cap
Number of subjects: 116

Group type: COMPARATOR
Intervention: 130 μm cap
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study: 28720558

Group type: EXPERIMENTAL
Intervention: Loop intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 48
Study: 26669201

Group type: EXPERIMENTAL
Intervention: Red-hot needle therapy combined with cupping
Number of subjects: 42

Group type: COMPARATOR
Intervention: Routine acupuncture combined with cupping
Number of subjects: 42
Study: 23123791

Group type: EXPERIMENTAL
Intervention: 12-week pragmatic exercise therapy intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study: 21996239

Group type: EXPERIMENTAL
Intervention: Caphosol (supersaturated calcium phosphate mouth rinse)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no Caphosol)
Number of subjects: 32
Study: 19055201

Group type: EXPERIMENTAL
Intervention: SABA nebulizer use
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: SABA MDI use
Number of subjects: 2056
Study: 16598620

Group type: EXPERIMENTAL
Intervention: Right ventricular DDD pacing in congestive heart failure patients (N=33)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Right ventricular DDD pacing in bradycardia patients (N=13)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cut-off interval of 135 ms
Number of subjects: 46
Study: 14519140

Group type: EXPERIMENTAL
Intervention: 1 g/day vitamin C
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 450 mg/day magnesium chelate
Number of subjects: 300

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 300
Study: 12651048

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone for 48 to 72 hours
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 10536541

Group type: EXPERIMENTAL
Intervention: AEPIndex
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 20
Study: 9053533

Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) in combination with beta-lactam antibiotics
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vancomycin (VCM) alone or in combination with another drug
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM) in combination with other antibiotics
Number of subjects: 52
Study: 2069371

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg) administered orally once daily for 5 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administered orally once daily for 5 days
Number of subjects: 16
Study: 6549638

Group type: EXPERIMENTAL
Intervention: Teaching-counseling program combined with exercise (early cardiac rehabilitation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (exercise only)
Number of subjects: 0
Study: 3947489

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (bupivacaine)
Number of subjects: 578

Group type: COMPARATOR
Intervention: General anaesthesia (enflurane or neurolept)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 578
Study: 29685141

Group type: EXPERIMENTAL
Intervention: Sinew acupuncture
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 86
Study: 28957960

Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Latanoprost/dorzolamide combination
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dorzolamide monotherapy
Number of subjects: 35
Study: 26151494

Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serum cortisol
Number of subjects: 41
Study: 23200843

Group type: EXPERIMENTAL
Intervention: Emergence of elevated liver function tests (LFTs)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Normal liver function tests (LFTs)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Emergence of elevated LFTs
Number of subjects: 376